Clomiphene Citrate for Post-Cycle Therapy After Anabolic Steroid Use
Clomiphene citrate (25-100 mg daily) is effective for post-cycle therapy (PCT) after anabolic steroid use, accelerating hormonal recovery and improving semen parameters compared to no treatment, with the addition of hCG providing superior outcomes for testicular volume and sperm recovery. 1
Evidence for Clomiphene in PCT
Mechanism and Rationale
Clomiphene citrate works by blocking estrogen receptors in the hypothalamus and pituitary, stimulating gonadotropin (LH and FSH) secretion, which increases endogenous testosterone production while preserving spermatogenesis 2, 3. This mechanism is critical after anabolic steroid use because it restores the suppressed hypothalamic-pituitary-gonadal axis without further suppressing testicular function 4, 3.
Clinical Outcomes in Steroid Users
The most recent and highest quality evidence comes from a 2026 dual-center retrospective cohort study of 79 recreational bodybuilders who used anabolic steroids for ≤6 months 1:
Hormonal recovery: Both clomiphene monotherapy (25 mg/day) and combination therapy (clomiphene + hCG) accelerated hormonal normalization compared to no treatment, with all groups achieving normal testosterone levels by 6 months 1
Semen parameter recovery: At 12 months, normozoospermia rates were significantly better with treatment:
- Clomiphene + hCG: 87.5%
- Clomiphene alone: 69.2%
- No treatment: 58.6% 1
Testicular volume: Combined therapy showed superior testicular recovery, with 70.8% achieving ≥20% volume increase versus only 6.9% with no treatment 1
Predictors of success: Combined clomiphene + hCG independently predicted normozoospermia (OR 6.23) and motility recovery (OR 4.85) 1
Dosing Protocols
Standard clomiphene dosing for PCT ranges from 25-100 mg daily 1, 4, 5:
25 mg daily: Effective for stimulating endogenous testosterone production with minimal side effects, raising testosterone from mean 309 ng/dL to 642 ng/dL after 3 months 5
100 mg daily: Used successfully in case reports of severe hypogonadism from steroid abuse, with documented restoration of the pituitary-gonadal axis 4
Duration: Minimum 2-3 months of treatment, with most studies showing continued benefit through 12 months 1, 5
Combination Therapy Considerations
Adding hCG (1500 IU subcutaneously three times weekly) to clomiphene provides superior outcomes for testicular volume recovery and semen parameters compared to clomiphene alone 1. This combination addresses both central stimulation (clomiphene) and direct testicular stimulation (hCG) 1.
For patients with severe spermatogenic suppression (FSH <1.5 IU/L), adding recombinant FSH (75 IU subcutaneously three times weekly) achieved normozoospermia in all treated patients by 12 months 1.
Safety Profile
Clomiphene is generally well-tolerated with few adverse effects 3:
Common side effects: Headache, dizziness, gynecomastia, and potential exacerbation of psychiatric conditions 3
Metabolic effects: May alter serum lipid profiles, though one study showed reduction in total cholesterol from 197 to 186 mg/dL after 3 months 6, 5
Contraindications: Liver disease (especially decompensated cirrhosis) is an absolute contraindication 6, 7
Long-term safety: Extended use beyond 3 years demonstrates maintained efficacy without decline in testosterone response 7
Clinical Algorithm for PCT
For men with documented normal pre-cycle reproductive function who used anabolic steroids ≤6 months:
First-line: Clomiphene citrate 25-50 mg daily for minimum 3 months 1, 5
Enhanced recovery: Add hCG 1500 IU subcutaneously three times weekly if faster testicular recovery or fertility is priority 1
Severe spermatogenic suppression: If FSH <1.5 IU/L after initial treatment, add recombinant FSH 75 IU subcutaneously three times weekly 1
Monitoring: Check testosterone, LH, FSH, and semen analysis at baseline, 3 months, 6 months, and 12 months 1
Important Caveats
Spontaneous recovery occurs without treatment in most cases, with hormonal normalization typically within 6-12 months after steroid cessation 1. However, PCT accelerates this recovery and improves final semen parameters 1.
The evidence base consists primarily of retrospective studies and case reports 1, 4. The 2026 study represents the largest cohort but acknowledges the need for prospective randomized trials to establish definitive protocols 1.
Baseline reproductive function matters: All evidence cited involved men with normal pre-cycle hormone levels and semen parameters 1. Outcomes may differ in men with pre-existing hypogonadism or infertility.